Thank you very much, Madam Chair.
There is something that I want to ask you about. The Patented Medicine Prices Review Board is having a cut of about 7.5%.
It would seem to me to be logical that they should get an increase, because they certainly need more resources to deal with the fact that the Auditor General has repeatedly said that the whole issue of adverse drug reporting is not timely and that more resources need to be added to it. I just want some sort of explanation as to why there's a cut in such an important area.
Thank you.